Viking Therapeutics VKTX AOCI - Available-for-Sale Securities, Net of Tax
AOCI - Available-for-Sale Securities, Net of Tax at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viking Therapeutics's aoci - available-for-sale securities, net of tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viking Therapeutics's AOCI - available-for-sale securities, net of tax?
- Viking Therapeutics (VKTX) reported AOCI - available-for-sale securities, net of tax of -$856K in Q1 2026.
- How has Viking Therapeutics's AOCI - available-for-sale securities, net of tax changed year-over-year?
- Viking Therapeutics's AOCI - available-for-sale securities, net of tax decreased by 296.3% year-over-year, from -$216K to -$856K.
- What is the long-term trend for Viking Therapeutics's AOCI - available-for-sale securities, net of tax?
- Over 5 years (2020 to 2025), Viking Therapeutics's AOCI - available-for-sale securities, net of tax has grown at a 47.6% compound annual growth rate (CAGR), from -$54K to $378K.